Page last updated: 2024-11-04

threonine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Threonine: An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

threonine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 1-hydroxyethyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6288
CHEMBL ID291747
CHEBI ID16857
CHEBI ID26986
SCHEMBL ID1480
MeSH IDM0021415

Synonyms (141)

Synonym
nsc-46701
AKOS015840277
l-(-)-threonine
CHEBI:16857 ,
l-alpha-amino-beta-hydroxybutyric acid
l-threonin
(2s,3r)-(-)-threonine
(2s)-threonine
l-2-amino-3-hydroxybutyric acid
(2s,3r)-2-amino-3-hydroxybutanoic acid
threonine, l-
nsc-16589
D00041
l-threonine (jp17)
threonine (usp)
threonine, dl-
threonin
butanoic acid, 2-amino-3-hydroxy-, (r-(r*,s*))-
threonine, l- (8ci)
2-amino-3-hydroxybutanoic acid, (r-(r*,s*))-
(2s,3r)-2-amino-3-hydroxybutyric acid
l-threonine (9ci)
[r-(r*,s*)]-2-amino-3-hydroxybutanoic acid
48: pn: wo2004076659 figure: 7 claimed sequence
(s)-threonine
l-thr
l-threonine ,
thre
threonine
2-amino-3-hydroxybutyric acid
72-19-5
C00188
l-threonine, reagent grade, >=98% (hplc)
l-threonine, from non-animal source, meets ep, jp, usp testing specifications, suitable for cell culture, 99.0-101.0%
DB00156
threonine (van)
treonina [spanish]
threonine [usan:inn]
threoninum [latin]
einecs 200-774-1
nsc 46701
nsc 16589
ai3-18477
einecs 201-300-6
nsc 206292
l-threonine, bioxtra, >=99.5% (nt)
AC-11296
3DD2E9AD-DB9A-460E-8A6B-C01B0F67AC4E
CHEMBL291747
fema no. 4710
threonine (l)
BMSE000049
T0230
h-thr-oh
2zd004190s ,
hsdb 7797
threoninum
unii-2zd004190s
treonina
BMSE000810
BMSE000859
tfm6du5s6a ,
unii-tfm6du5s6a
ccris 8603
tox21_112154
dtxsid2046412 ,
dtxcid0026412
cas-72-19-5
AKOS006240505
pharmakon1600-01301008
nsc-760118
nsc760118
l-(u-14c)threonine
7013-32-3
threonine, labeled with carbon-14, l-
AM20100684
threonine [who-dd]
l-threonine [jan]
threonine [mi]
lysine hydrochloride impurity c [ep impurity]
threonine [vandf]
threonine [inn]
(r-(r*,s*))-2-amino-3-hydroxybutanoic acid
l-threonine [usp-rs]
threonine [ep monograph]
threonine [mart.]
threonine [hsdb]
threonine [inci]
threonine [ii]
threonine [usan]
l-threonine [fcc]
threonine [usp monograph]
(+/-)-threonine
S4951
gtpl4785
CCG-214540
SCHEMBL1480
tox21_112154_1
h-thr
l-thr-oh
Q-201331
CS-W020046
l-threonine;
F8881-8883
mfcd00064270
l-threonine (h-thr-oh)
M02962
l-threonine, certified reference material, tracecert(r)
l-threonine, united states pharmacopeia (usp) reference standard
l-threonine non-animal source
l-threonine, european pharmacopoeia (ep) reference standard
l-threonine, vetec(tm) reagent grade, >=98%
l-threonine, pharmaceutical secondary standard; certified reference material
l-threonine, p.a., 99.0-101.0%
2-amino-3-hydroxybutanoate
l-alpha-amino-beta-hydroxybutyrate
(r-(r*,s*))-2-amino-3-hydroxybutanoate
[r-(r*,s*)]-2-amino-3-hydroxy-butanoic acid
l-2-amino-3-hydroxybutyrate
(2s,3r)-2-amino-3-hydroxybutyrate
[r-(r*,s*)]-2-amino-3-hydroxybutanoate
2-amino-3-hydroxybutyrate
[r-(r*,s*)]-2-amino-3-hydroxy-butanoate
DTXSID70893087
l-threonine,(s)
AS-12789
Q186521
(2s,3r)-rel-2-amino-3-hydroxybutanoic acid
HY-N0658
AC7878
threonine (l-threonine)
EN300-54609
(2s,3r)-rel-2-amino-3-hydroxybutanoicacid
threonine (ii)
threonine (ep monograph)
threonine (usp monograph)
chebi:26986
threonine (mart.)
threoninum (latin)
beta-methylserine
Z813019058

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"90% threonine to the high tyrosine diet, growth was significantly improved and toxic lesions were completely prevented."( Effect of individual amino acid supplements on the toxicity of excess tyrosine in rats.
Arito, T; Muramatsu, K; Tsuda, H, 1976
)
0.26
" Incubation for 7 days with 10(-5) M Cu had a similar toxic effect."( Copper exchanges and toxicity in the rabbit lens in vitro.
Bentley, PJ; Cook, CS, 1986
)
0.27
"The goal of this randomized, double-blind crossover clinical trial in 50 healthy volunteers sensitive to acidic foods was to evaluate whether Ester-C calcium ascorbate causes fewer epigastric adverse effects than are produced by regular ascorbic acid (AA)."( Safety and tolerance of ester-C compared with regular ascorbic acid.
Bentley, C; Busch, R; Graubaum, HJ; Gruenwald, J,
)
0.13
"Mefloquine, a drug used for treatment and prophylaxis of malaria, is known for its neuropsychiatric adverse effects."( MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine.
Aarnoudse, AL; Dieleman, J; Ligthelm, RJ; Molokhia, M; Overbosch, D; Stricker, BH; van der Heiden, IP; van Riemsdijk, MM; van Schaik, RH, 2006
)
0.33
"The association between MDR1 C1236T, G2677T, and C3435T single-nucleotide polymorphisms and the occurrence of neuropsychiatric adverse effects was examined in a prospective cohort study of 89 healthy white travelers taking mefloquine."( MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine.
Aarnoudse, AL; Dieleman, J; Ligthelm, RJ; Molokhia, M; Overbosch, D; Stricker, BH; van der Heiden, IP; van Riemsdijk, MM; van Schaik, RH, 2006
)
0.33
"Of the subjects, 27 (28%) reported neuropsychiatric adverse effects, women significantly more frequently than men."( MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine.
Aarnoudse, AL; Dieleman, J; Ligthelm, RJ; Molokhia, M; Overbosch, D; Stricker, BH; van der Heiden, IP; van Riemsdijk, MM; van Schaik, RH, 2006
)
0.33
"In this study the MDR1 1236TT, 2677TT, and 3435TT genotypes, along with the 1236-2677-3435 TTT haplotype, were associated with neuropsychiatric adverse effects of mefloquine in women."( MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine.
Aarnoudse, AL; Dieleman, J; Ligthelm, RJ; Molokhia, M; Overbosch, D; Stricker, BH; van der Heiden, IP; van Riemsdijk, MM; van Schaik, RH, 2006
)
0.33
" We investigated the basis for these other phenotypes and found that they are dependent on the toxic biosynthetic intermediate homoserine."( Homoserine toxicity in Saccharomyces cerevisiae and Candida albicans homoserine kinase (thr1Delta) mutants.
Kingsbury, JM; McCusker, JH, 2010
)
0.36
" No mortalities or evidence of adverse effects were observed in Sprague-Dawley (SD) rats following acute oral administration of 2000 mg of NAT/kg of body weight (kg of bw)."( Safety assessment of N-acetyl-L-threonine.
Barnett, JF; Delaney, BF; Krsmanovic, L; Myhre, A; Shen, ZA; van de Mortel, EL, 2010
)
0.36
"In epilepsy, traumatic brain injury, and ischemic stroke, toxic levels of zinc released from neurons contribute to the brain damage associated with these disorders."( Histidine, cystine, glutamine, and threonine collectively protect astrocytes from the toxicity of zinc.
Bishop, GM; Campbell, MS; Ralph, DM; Robinson, SR, 2010
)
0.36
" No significant changes in body weight, food consumption, organ weight, relative organ weight, hematology, blood biochemistry, histopathology, behavior, mortality, sperm abnormality, mutagenicity, and micronucleus formation were observed and no clinical signs or adverse effects were detected."( Safety evaluation of zinc threoninate chelate.
Gong, Y; Hu, XB; Li, L; Nie, SP; Wang, YX; Xie, MY, 2010
)
0.36
" No adverse events related to the study formula were reported."( Safety and adequacy of an optimized formula for pediatric patients with cow's milk-sensitive enteropathy.
Plaskie, K; Vandenplas, Y, 2010
)
0.36
"These results show that New Alfaré is safe and nutritionally adequate for pediatric patients with cow's milk-sensitive enteropathy."( Safety and adequacy of an optimized formula for pediatric patients with cow's milk-sensitive enteropathy.
Plaskie, K; Vandenplas, Y, 2010
)
0.36
" There were no adverse events associated with supplementation and horses in both groups showed normal weight gain, clinical signs, hematology and chemistry."( Seventy day safety assessment of an orally ingested, l-glutamine-containing oat and yeast supplement for horses.
Anderson, SC; Lindinger, MI, 2014
)
0.4
" The most toxic compound analyzed showed about 50 times less cytotoxicity than the cisplatin reference compound in HT-29 cells."( Cytotoxicity studies of water soluble coordination compounds with a [Mo2O2S2](2+) core.
Bobersky, S; Gretarsdóttir, JM; Metzler-Nolte, N; Suman, SG, 2016
)
0.43
" CAT tail aggregation has been hypothesized to either protect cells by sequestering potentially toxic incomplete polypeptides or harm cells by disrupting protein homeostasis."( Aggregation of CAT tails blocks their degradation and causes proteotoxicity in S. cerevisiae.
Brandman, O; Giafaglione, JM; Park, JH; Sitron, CS, 2020
)
0.56
"Acrolein (ACR) and formaldehyde (FA) are toxic aldehydes co-produced in foods."( Cytotoxicity of a Novel Compound Produced in Foods via the Reaction of Amino Acids with Acrolein along with Formaldehyde.
Hu, J; Ou, J; Ou, S, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" Taken together, the amino acid transporter-targeting gemcitabine prodrug, Gem-Thr, was found to be effective on pancreatic cancer cells and to offer an efficient potential means of treating pancreatic cancer with significantly better pharmacokinetic characteristics than gemcitabine."( Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties.
Fang, Z; Hong, S; Hong, SS; Jung, HY; Maeng, HJ; Yoon, JH, 2018
)
0.48

Compound-Compound Interactions

ExcerptReferenceRelevance
"The present study examined the anti-herpetic effect of the glycoprotein inhibitors, hydroxynorvaline and 2-deoxyglucose, alone and in combination with trifluridine on murine ocular herpes."( Efficacy of glycoprotein inhibitors alone and in combination with trifluridine in the treatment of murine herpetic keratitis.
Araullo-Cruz, T; Blough, HA; Cheng, KP; Gordon, YJ; Johnson, BJ; Romanowski, E, 1986
)
0.27
" Alternatively, molecular dynamics simulation combined with dynamic fluorescence spectroscopy revealed that 14-3-3 zeta C-terminal stretch is directly involved in the interaction of 14-3-3 protein with the ligand."( Protein modeling combined with spectroscopic techniques: an attractive quick alternative to obtain structural information.
Amler, E; Kubala, M; Lánský, Z; Obsil, T; Obsilová, V, 2004
)
0.32
"Preclinical and clinical studies have shown that proteasome inhibitors (PIs) have anti-MM activity in combination with dexamethasone or lenalidomide."( CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.
Berenson, JR; Chen, H; Hunter, K; Jones-Bolin, S; Li, J; Li, M; Ruggeri, B; Sanchez, E; Wang, C, 2012
)
0.38
" The aim of the present study was to assess the relationship between this polymorphism and peripheral atherosclerosis combined with type 2 diabetes mellitus (T2DM) in an Egyptian population."( Intestinal fatty acid binding protein Ala54Thr polymorphism is associated with peripheral atherosclerosis combined with type 2 diabetes mellitus.
Abo-Elmatty, DM; Ghattas, MH; Khattab, SA; Mehanna, ET; Mesbah, NM, 2017
)
0.46
"The Thr54 allele of the FABP2 Ala54Thr polymorphism was associated with an increased incidence of peripheral atherosclerosis combined with T2DM in the population studied."( Intestinal fatty acid binding protein Ala54Thr polymorphism is associated with peripheral atherosclerosis combined with type 2 diabetes mellitus.
Abo-Elmatty, DM; Ghattas, MH; Khattab, SA; Mehanna, ET; Mesbah, NM, 2017
)
0.46
" These variants were subsequently combined with replacement of the cysteine 481 residue to which irreversible inhibitors, such as ibrutinib, acalabrutinib and zanubrutinib, bind."( BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
Berglöf, A; Estupiñán, HY; Mohammad, DK; Schaafsma, GCP; Shi, Y; Smith, CIE; Vihinen, M; Wang, Q; Yu, L; Zain, R; Zhou, L, 2021
)
0.62

Bioavailability

The bioavailability of threonine in solvent-extracted soybean meal for 10- to 20-kg pigs was determined using the slope-ratio method. Zn bioavailability and performance of broiler chicks was compared.

ExcerptReferenceRelevance
" The rate of absorption of from two to six of the amino acids tested was lower in 7 of the patients than in the control subjects."( Malabsorption of essential amino acids in tropical sprue.
Corcino, JJ; Klipstein, FA, 1975
)
0.25
"The bioavailability of threonine in soybean meal and the effects of the excess amino acids in soybean meal on the estimate were measured using rats and chicks in slope-ratio assays."( Bioavailability of threonine in soybean meal for rats and chicks.
Lewis, AJ; Radke, TR, 1992
)
0.28
"1 g C/d) was approximately three times the estimated rate of absorption of exogenous threonine (1 g C/d)."( Threonine metabolism in sheep. I. Threonine catabolism and gluconeogenesis in mature Blackface wethers given poor quality hill herbage.
Egan, AR; Lamb, CS; MacRae, JC, 1983
)
0.27
"The bioavailability of threonine in solvent-extracted soybean meal for 10- to 20-kg pigs was determined using the slope-ratio method."( Bioavailability of threonine in soybean meal for young pigs.
Kovar, JL; Lewis, AJ; Miller, PS; Radke, TR, 1993
)
0.29
" It appears likely that there is a gap in the bioavailability of oligomethionine between the octamer and nonamer when added to a low-protein diet, probably due to the rigidity of the structure increasing with the polymerization degree by alpha-helix formation."( Polymerization degree of oligomethionine to determine its bioavailability when added to a low-protein diets.
Kasai, T; Kiriyama, S; Tanaka, T, 1996
)
0.29
"On the basis of in vitro studies indicating that dipyridamole is an inhibitor for the MDR1 efflux membrane transporter P-glycoprotein, we postulated that dipyridamole could increase the bioavailability of digoxin, a P-glycoprotein substrate."( Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition.
Becquemont, L; Brinkmann, U; Dubert, L; El-Morabet, H; Funck-Brentano, C; Jaillon, P; Kerb, R; Strabach, S; Trugnan, G; Verstuyft, C, 2003
)
0.32
"The main objective was to determine whether dipyridamole alters the bioavailability of digoxin."( Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition.
Becquemont, L; Brinkmann, U; Dubert, L; El-Morabet, H; Funck-Brentano, C; Jaillon, P; Kerb, R; Strabach, S; Trugnan, G; Verstuyft, C, 2003
)
0.32
"Selective endothelial insulin resistance is sufficient to induce a reduction in NO bioavailability and endothelial dysfunction that is secondary to increased generation of reactive oxygen species."( Effect of endothelium-specific insulin resistance on endothelial function in vivo.
Anilkumar, N; Crossey, PA; Douglas, G; Duncan, ER; Ezzat, VA; Kearney, MI; Kearney, MT; Poston, L; Shah, AM; Walker, S; Wheatcroft, SB, 2008
)
0.35
"Hyperglycaemia is known to reduce nitric oxide (NO) bioavailability by modulating endothelial NO synthase (eNOS) activity, and polyphenols are believed to have cardiovascular benefit."( Beneficial effect of the oligomerized polyphenol oligonol on high glucose-induced changes in eNOS phosphorylation and dephosphorylation in endothelial cells.
Fujii, H; Hattori, Y; Hayashi, T; Matsuda, N; Nishioka, H; Yokoo, H; Zhang, XH, 2010
)
0.36
" However, requirement recommendations must be accompanied by an estimate of the bioavailability of AA from feeds to ensure adequate supply of AA and to minimize excess nitrogen excretion."( The metabolic availability of threonine in common feedstuffs fed to adult sows is higher than published ileal digestibility estimates.
Ball, RO; Levesque, CL; Moehn, S; Pencharz, PB, 2011
)
0.37
"We examined whether changes in the gut microbiota induced by clinically relevant interventions would impact the bioavailability of dietary amino acids in neonates."( Modulation of the gut microbiota with antibiotic treatment suppresses whole body urea production in neonatal pigs.
Boehm, G; Boye, M; Burrin, D; de Bruijn, A; Mølbak, L; Puiman, P; Renes, I; Schierbeek, H; Stoll, B; van Goudoever, J, 2013
)
0.39
" It is well established that reduced vascular endothelial nitric oxide (NO) bioavailability promotes arterial inflammation; however, the role of NO in modulating inflammation in AT remains disputed."( Ablation of eNOS does not promote adipose tissue inflammation.
Gastecki, ML; Jurrissen, TJ; Padilla, J; Rector, RS; Sheldon, RD; Vieira-Potter, VJ; Woodford, ML; Zidon, TM, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The purpose of this study was to compare zinc sulfate and zinc threonine chelate based on Zn bioavailability and performance of broiler chicks."( Comparison of Zinc Sulfate and Zinc Threonine Based on Zn Bioavailability and Performance of Broiler Chicks.
Esfahani, MB; Farhadi Javid, S; Ghaffarzadeh, M; Moravej, H, 2021
)
0.62

Dosage Studied

A dose-response experiment was conducted to investigate the impacts of dietary threonine (Thr) levels on growth performance, serum biochemical indices, antioxidant capacities, and gut morphology of broiler chickens. Purified Pak1 kinase promotes the phosphorylation of the Snf1 polypeptide on Threonine 210 within the activation loop in vitro. An increased dosage of the PAK1 gene causes increased Snf 1 threxine 210 phosphorylated in vivo.

ExcerptRelevanceReference
" Hypophenylalaninemia was unexplained, and failed to respond to increased phenylpyruvate dosage or phenylalanine itself; renal clearance of phenylalanine was high but could not account for the low plasma level."( Long-term management of a case of carbamyl phosphate synthetase deficiency using ketanalogues and hydroxyanalogues of essential amino acids.
Batshaw, ML; Brusilow, S; Walser, M, 1976
)
0.26
" Intake of imbalanced diet was increased from 45-50 to 70-75% of baseline after bilateral injection of the DLAA directly into the PPC, following an inverted U-shaped dose-response curve."( Effect of dietary limiting amino acid in prepyriform cortex on food intake.
Beverly, JL; Gietzen, DW; Rogers, QR, 1990
)
0.28
" 33P-O-phosphothreonine was also identified in experiments using a dosage of 10 mCi per embryo."( Radioautographic visualization and biochemical identification of O-phosphoserine- and O-phosphothreonine-containing phosphoproteins in mineralizing embryonic chick bone.
Brickley-Parsons, D; Glimcher, MJ; Landis, WJ; Sanzone, CF, 1984
)
0.27
" Replacement of the leucine in any one subunit slows desensitization and shifts the dose-response relationship toward lower concentrations."( The role of conserved leucines in the M2 domain of the acetylcholine receptor in channel gating.
Filatov, GN; White, MM, 1995
)
0.29
" Co-expression of the mutants with beta 2 and gamma 2 subunits in human embryonic kidney cells produced functional receptors which are similar to the wild type in their sensitivity to a benzodiazepine agonist (U-92330), insensitivity to Zn, anion permeability, and GABA dose-response profiles as monitored with the whole cell patch clamp technique."( Acceleration of GABA-dependent desensitization by mutating threonine 266 to alanine of the alpha 6 subunit of rat GABAA receptors.
Altman, RA; Binder, JA; Dillon, GH; Im, HK; Im, WB; Pregenzer, JF, 1995
)
0.29
" Dose-response curves were generated using six 4 x 4 Latin squares."( Dietary crude protein increases slightly the requirement for threonine in kittens.
Hammer, VA; Morris, JG; Rogers, QR, 1996
)
0.29
" However, the corresponding ligand dose-response curve for dexamethasone-induced transactivation was shifted to higher concentrations when compared with that obtained with the wild type GR."( Mutation of isoleucine 747 by a threonine alters the ligand responsiveness of the human glucocorticoid receptor.
Balaguer, P; Chambon, P; Gronemeyer, H; Jausons-Loffreda, N; Nicolas, JC; Pons, M; Roux, S; Térouanne, B, 1996
)
0.29
" Our objectives were: (1) to determine whether injections of the DLAA threonine into the lateral hypothalamus (LH) alter intake of a threonine-devoid diet (DEV); and (2) to examine the dose-response effects of threonine injections into the LH on intake of threonine-corrected diet (COR)."( Effects of threonine injections in the lateral hypothalamus on intake of amino acid imbalanced diets in rats.
Barrett, JA; Blevins, JE; Dixon, KD; Gietzen, DW; Hernandez, EJ, 2000
)
0.31
" The beta(2)AR polymorphism significantly affected the dose-response curves for terbutaline-induced inotropic and chronotropic responses: compared with WT individuals, subjects with the Thr164Ile receptor had substantial blunting in maximal increases in heart rate (WT, 29."( Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors.
Brodde, OE; Büscher, R; Dhein, S; Insel, PA; Radke, J; Tellkamp, R, 2001
)
0.31
" Using L-threonine and L-glutamine as representative amino acids, this study was undertaken to estimate apparent simple diffusion of L-amino acids and to establish the effective dosage of HgCl2 for completely blocking carrier-mediated L-amino acid transport in porcine jejunal enterocyte brush border membrane vesicles."( Estimation of apparent L-amino acid diffusion in porcine jejunal enterocyte brush border membrane vesicles.
Asem, EK; Fan, MZ, 2001
)
0.31
"The discovery of a functional single-nucleotide polymorphism in the cyclooxygenase 1 locus may ultimately improve the safe and effective use of acetylsalicylic acid by better tailoring of dosage with an individual's genetic variation."( Genetic variation in cyclooxygenase 1: effects on response to aspirin.
Halushka, MK; Halushka, PV; Walker, LP, 2003
)
0.32
" Purified Pak1 kinase promotes the phosphorylation of the Snf1 polypeptide on threonine 210 within the activation loop in vitro, and an increased dosage of the PAK1 gene causes increased Snf1 threonine 210 phosphorylation in vivo."( Yeast Pak1 kinase associates with and activates Snf1.
McCartney, RR; Nath, N; Schmidt, MC, 2003
)
0.32
" Glutamate dose-response curves from NR1a/NR2D(T692A) receptor channels produced an approximately 1600-fold reduction in glutamate potency compared to wild-type NR1a/NR2D receptors."( Influence of a threonine residue in the S2 ligand binding domain in determining agonist potency and deactivation rate of recombinant NR1a/NR2D NMDA receptors.
Chen, PE; Johnston, AR; Mok, MH; Schoepfer, R; Wyllie, DJ, 2004
)
0.32
"25 mumol/L UCN-01, glucose transport is inhibited 66, 29, and 26% at insulin concentrations of 10, 50, and 100,000 (100K) microunits/mL respectively, thus shifting the dose-response curve to the right."( 7-hydroxystaurosporine (UCN-01) inhibition of Akt Thr308 but not Ser473 phosphorylation: a basis for decreased insulin-stimulated glucose transport.
Cushman, SW; Kondapaka, SB; Sausville, EA; Yver, DR; Zarnowski, M, 2004
)
0.32
" Dose-response curves in myometrial cells expressing the endogenous OTR indicated a significant effect of OT on eukaryotic elongation factor 2 dephosphorylation at 1 nM, a concentration close to the dissociation constant (K(d)) of OT."( Oxytocin induces dephosphorylation of eukaryotic elongation factor 2 in human myometrial cells.
Carrier, ME; Devost, D; Girotti, M; Russo, C; Zingg, HH, 2005
)
0.33
"In addition to dose-response studies, modeling of N utilization, depending on intake of the first limiting amino acid in the diet, is one of the tools for assessing amino acid requirements in growing animals."( Modeling of threonine requirement in fast-growing chickens, depending on age, sex, protein deposition, and dietary threonine efficiency.
Liebert, F, 2006
)
0.33
"Our results strongly suggest an association between the Ala54Thr polymorphism of FABP2 with diabetes, revealing a genetic dosage effect regarding its association with diabetes in Chilean elders."( FABP2 Ala54Thr polymorphism and diabetes in Chilean elders.
Albala, C; Angel, B; Lera, L; Liberman, C; Pérez-Bravo, F; Sanchez, H; Santos, JL; Villarroel, A, 2007
)
0.34
" Time-course and dose-response experiments indicate that DARPP-32 phosphorylation is maximal 30 min following administration of 10mg/kg of THC."( Regulation of DARPP-32 phosphorylation by Delta9-tetrahydrocannabinol.
Borgkvist, A; Fisone, G; Fuxe, K; Greengard, P; Marcellino, D, 2008
)
0.35
" All genes were sequenced bi-directionally, and, additionally, SNCA, PRKN and PINK1 were subjected to gene dosage analysis."( Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2.
Bras, J; Calado, A; Dias, M; Guerreiro, R; Hardy, J; Januario, C; Morgadinho, A; Oliveira, C; Ribeiro, M; Semedo, C; Singleton, A, 2008
)
0.35
" We provide evidence that changes in Dyrk1A gene dosage in the mouse strongly alter the cellularity of inner retina layers and result in severe functional alterations."( The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development.
Aranda, S; Arbonés, ML; Barallobre, MJ; Barhoum, R; de la Luna, S; de la Villa, P; Delabar, JM; Fernández, E; Fotaki, V; Laguna, A, 2008
)
0.35
" A data set containing 92 dose-response treatments was extracted from the literature, compiled, and entered into the training and testing sets of the ANN models."( The integration of broiler chicken threonine responses data into neural network models.
Ahmadi, H; Golian, A, 2010
)
0.36
" Three experiments were performed: experiments 1 and 2 to investigate the dose-response of threonine supplementation during infection and experiment 3 to validate the threonine requirement during infection."( Threonine requirement of broiler chickens during subclinical intestinal Clostridium infection.
Corrent, E; Rovers, M; Star, L; van der Klis, JD, 2012
)
0.38
"In a dose-response study, dietary levels of standardized ileal digestible methionine (dMet), lysine (dLys), and threonine (dThr) were optimized by response surface methodology (RSM) using a central composite rotatable design in starting broiler chicks that were feed-deprived 2 d posthatch."( Estimation of ideal ratios of methionine and threonine to lysine in starting broiler chicks using response surface methodology.
Davarpanah, AA; Mehri, M; Mirzaei, HR, 2012
)
0.38
" Reduced cholesterol did not change the MC4R dose-response curve to α-MSH, but it decreased the amount of cAMP generated per receptor number indicating that a population of MC4R at the cell surface becomes nonfunctional."( Constitutive cholesterol-dependent endocytosis of melanocortin-4 receptor (MC4R) is essential to maintain receptor responsiveness to α-melanocyte-stimulating hormone (α-MSH).
Baldini, G; Granell, S; McDaniel, FK; McPike, L; Mohammad, S; Molden, BM; Narducci, P, 2012
)
0.38
" Non-diabetic mice were administered increasing doses of insulin to define a dose-response relationship between insulin and Akt activation in the dorsal root ganglion (DRG) and sciatic nerve."( In vivo peripheral nervous system insulin signaling.
Grote, CW; Ryals, JM; Wright, DE, 2013
)
0.39
" Dependent on its kinase activity and correlated with the dosage of overexpression, DYRK1A blocked proliferation of SH-SY5Y neuroblastoma cells within 24 h and arrested the cells in G₁ phase."( The Down syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and Cyclin D1 and induces cell cycle exit and neuronal differentiation.
Becker, W; Florencio Ortiz, V; Pasqualon, T; Schumacher, J; Soppa, U; Tejedor, FJ, 2014
)
0.4
" A dose-response experiment with 5 dietary threonine concentrations (5."( Threonine requirement of White Pekin ducks from hatch to 21 d of age.
Hou, SS; Huang, W; Tang, J; Wen, ZG; Xie, M; Zhang, L, 2014
)
0.4
" The MT expression was induced in a dose-response and time-dependent manner upon various metal treatments."( Heavy metal-induced metallothionein expression is regulated by specific protein phosphatase 2A complexes.
Bai, Q; Chen, L; Chen, W; Gao, C; He, Z; Li, D; Li, J; Liu, C; Ma, L; Qu, W; Wei, Q; Xiao, Y; Zeng, X; Zhang, A; Zhang, J; Zhang, Z; Zhu, X; Zhuang, Z, 2014
)
0.4
"A dose-response experiment was conducted to investigate the impacts of dietary threonine (Thr) levels on growth performance, serum biochemical indices, antioxidant capacities, and gut morphology of broiler chickens."( Effects of dietary threonine levels on growth performance, serum biochemical indexes, antioxidant capacities, and gut morphology in broiler chickens.
Gao, YP; Liu, SG; Meng, GH; Min, YN; Qu, ZX, 2017
)
0.46
"The aim of the study was to investigate the endogenous metabolites of patients with psoriasis vulgaris which will be helpful for the diagnosis of the disease and to provide the evidence of pathogenesis and the formulation for the individualized dosage regimen."( Identification of psoriasis vulgaris biomarkers in human plasma by non-targeted metabolomics based on UPLC-Q-TOF/MS.
Li, H; Li, SS; Liu, Y; Wang, LP; Wu, XS; Xue, LF; Yin, GS, 2019
)
0.51
" Dose-response validation of the top candidate, quizartinib, was conducted in two cell lines of HT-22 and MEFs."( Quizartinib inhibits necroptosis by targeting receptor-interacting serine/threonine protein kinase 1.
Fu, S; Gu, T; He, X; Hu, X; Li, M; Mou, Y; Wang, J; Wei, J; Xiao, X; Ye, Z; You, X; Yu, Y; Zha, Y; Zhu, G, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (8)

RoleDescription
nutraceuticalA product in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance.
micronutrientAny nutrient required in small quantities by organisms throughout their life in order to orchestrate a range of physiological functions.
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
algal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in algae including unicellular organisms like chlorella and diatoms to multicellular organisms like giant kelps and brown algae.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
amino acid zwitterionThe zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group.
threonineAn alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 1-hydroxyethyl group.
L-alpha-amino acidAny alpha-amino acid having L-configuration at the alpha-carbon.
aspartate family amino acidAn L-alpha-amino acid which is L-aspartic acid or any of the essential amino acids biosynthesised from it (asparagine, lysine, methionine, threonine and isoleucine). A closed class.
proteinogenic amino acidAny of the 23 alpha-amino acids that are precursors to proteins, and are incorporated into proteins during translation. The group includes the 20 amino acids encoded by the nuclear genes of eukaryotes together with selenocysteine, pyrrolysine, and N-formylmethionine. Apart from glycine, which is non-chiral, all have L configuration.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (30)

PathwayProteinsCompounds
Threonine and 2-Oxobutanoate Degradation814
Inner Membrane Transport7862
tRNA Charging5227
tRNA Charging 22225
Threonine Biosynthesis1123
Isoleucine Biosynthesis1622
Secondary Metabolites: Threonine Biosynthesis from Aspartate715
L-Threonine Degradation to Methylglyoxal212
Glycine Metabolism1127
Threonine Metabolism619
Glycine and Serine metabolism ( Glycine and Serine metabolism )3649
Biomarkers for urea cycle disorders1222
Protein Synthesis: Threonine804
mRNA, protein, and metabolite inducation pathway by cyclosporin A213
tRNA charging pathway023
superpathway of threonine degradation011
threonine degradation I08
threonine degradation II04
threonine degradation IV08
threonine degradation III (to methylglyoxal)012
superpathway of threonine metabolism034
superpathway of lysine, threonine and methionine biosynthesis II032
isoleucine biosynthesis I024
superpathway of lysine, threonine and methionine biosynthesis I038
threonine biosynthesis016
aminopropanol biosynthesis08
isoleucine biosynthesis I (from threonine)015
Sulfate assimilation and copper detoxification020
AtMetExpress overview0109
Biochemical pathways: part I0466
Amino acid metabolism094

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency16.35350.003041.611522,387.1992AID1159552
activating transcription factor 6Homo sapiens (human)Potency0.04140.143427.612159.8106AID1159516
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1149043Retardation factor of the compound in cyclohexylamine-water-methyl ethyl ketone-1-butanol at 1:2.5:5:5 ratio by paper chromatography1976Journal of medicinal chemistry, Feb, Volume: 19, Issue:2
Racemic diastereoisomers of 1-amino-2-hydroxycyclopentanecarboxylic acid.
AID500825Induction of nitrogen-starved wild type sigma1278b yeast Gap1-mediated trehalose activation at 10 mM2009Nature chemical biology, Jan, Volume: 5, Issue:1
Transport and signaling via the amino acid binding site of the yeast Gap1 amino acid transceptor.
AID26797Partition coefficient (logP)1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID233320Bitter threshold value; NB denotes 'Not bitter'1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID157604Compound was evaluated for the inhibition of Phenylalanine dehydrogenase of Sporosarcina species1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Synthesis of probes for the active site of leucine dehydrogenase.
AID1881860Inhibition of PKM2 (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
AID681113TP_TRANSPORTER: inhibition of L-tryptophan uptake in Xenopus laevis oocytes2001The Journal of biological chemistry, May-18, Volume: 276, Issue:20
Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10,160)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902951 (29.05)18.7374
1990's1623 (15.97)18.2507
2000's3156 (31.06)29.6817
2010's1906 (18.76)24.3611
2020's524 (5.16)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials98 (0.94%)5.53%
Reviews316 (3.04%)6.00%
Case Studies175 (1.69%)4.05%
Observational1 (0.01%)0.25%
Other9,793 (94.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]